Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

5 May 2009 07:00

RNS Number : 5915R
ViaLogy PLC
05 May 2009
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

Accuracy of latest oil well predictions independently confirmed

LondonMay 5, 2009Vialogy (LSE:VIY) Following the announcement on 23 April 2009 that a further oil discovery had been made on the Galba Field, Texas ("Mary Ridgeway #1"), ViaLogy is pleased to announce that it has now received detailed analysis confirming the predictions made using its QuantumRD technology on the oil find The successful well was drilled by the leaseholders, Atascosa Exploration LLC of San Antonio.

Using industry standard core analysis practices, Atascosa has received independent confirmation that the well will produce 170,000 barrels of crude oil (i.e. 35% primary recovery based on an overall actual volume of 486,000 barrels).  Atascosa plans extractions of 50% of the recoverable reserves in first three years.  ViaLogy's QuantumRD predictions of hydrocarbon pay zones at depth of 3050 feet with average porosity of 30%, and the oil reservoir's boundaries all proved correct.  With a 10% direct working Interest, ViaLogy expects to receive revenues of approximately $650,000, assuming 35% recovery, over the life of the well (assuming an average per barrel price of $50) to be paid monthly and to begin in Q2 2009.

Atascosa's Senior Geologist, Wilford Stapp commented, "I am very impressed by ViaLogy's ability to combine geological assessment with subsurface seismic interpretation to locate hydrocarbon high saturation zones in consolidated sands.  We have concluded that Mary Ridgeway #1 is a new isolated reservoir in the Bartosh formation with multiple pay zones. ViaLogy's optimized drill location has ensured that this new well will not compete with other producing wells, enhancing our total recovery from the field." Mr. Stapp has Emeritus standing with both the American Association of Petroleum Geologists and Society of Petroleum Engineers; he founded the Publication of the South Texas Geological Society, and was a Fellow of Geological Society of London.  He has been an expert practicing geologist for over 50 years working with majors and independents.  Besides Texas, Mr Stapp has worked in AsiaAustraliaDominican RepublicEnglandFranceMoroccoNamibia, and the Persian Gulf.

ViaLogy has also agreed terms with Atascosa for the drilling of a third well on the Galba Field and discussions are under way for the application of QuantumRD at a number of other Atascosa lease sites.  In addition, Vialogy expects to be working with other customers on additional oil discovery projects in the coming weeks.

Vialogy CEO, Robert Dean, commented, "The accuracy of ViaLogy's QuantumRD analysis and predictions on these first successful wells is impressive.  The technology is widely applicable, and the Company intends to demonstrate its capabilities with an increasing variety of hydrocarbon geological formations and an expanded customer set." 

For further information please contact:

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656)

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC (St. Helen's Capital)

Ruari McGirr / Sebastian Wykeham +44 (0) 207 628 5582  

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLUUUCAAUPBGUG
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.